Literature DB >> 9707500

Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells.

H C Thomas1, M W Lamé, S K Dunston, H J Segall, D W Wilson.   

Abstract

In the monocrotaline (MCT) model of pulmonary hypertension, the pulmonary vascular endothelium is the likely early target of the reactive metabolite monocrotaline pyrrole (MCTP). Incubation of cultured bovine pulmonary arterial endothelial cells (BPAEC) with MCTP results in covalent binding to DNA, cell cycle arrest, and delayed but progressive cell death. The mode of cell death in MCTP-induced endothelial damage has not been addressed previously. Since DNA damage is frequently associated with apoptosis, the presence or absence of apoptosis in adherent BPAEC was determined by several techniques, including morphologic and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling. Two concentrations of MCTP (5 and 34.5 microgram/ml) along with a vehicle control were examined with each assay. Both concentrations of MCTP induced increasing numbers of cells to undergo apoptosis over time beginning as early as 6 h after exposure to MCTP in the high concentration group. Control and vehicle control cells exhibited small amounts of apoptosis (1-2%), which did not change over the duration of the experiment. Additionally, cell membrane integrity was assessed over time by either exposure to membrane-impermeant dyes or measuring LDH release. By either method, BPAEC had increased membrane permeability after about 48 h of either low or high concentration MCTP exposure. We conclude that both a low or high concentration of MCTP causes cell death in BPAEC by inducing apoptosis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707500     DOI: 10.1006/taap.1998.8458

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  16 in total

1.  The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.

Authors:  Pascal Guerard; Zo Rakotoniaina; Françoise Goirand; Luc Rochette; Monique Dumas; Frederic Lirussi; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-08-01       Impact factor: 3.000

2.  Gene delivery of cytochrome p450 epoxygenase ameliorates monocrotaline-induced pulmonary artery hypertension in rats.

Authors:  Changlong Zheng; Luyun Wang; Rui Li; Ben Ma; Ling Tu; Xizhen Xu; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-29       Impact factor: 6.914

3.  C-type natriuretic peptide does not attenuate the development of pulmonary hypertension caused by hypoxia and VEGF receptor blockade.

Authors:  Brian Casserly; Jeffrey M Mazer; Alexander Vang; Elizabeth O Harrington; James R Klinger; Sharon Rounds; Gaurav Choudhary
Journal:  Life Sci       Date:  2011-07-27       Impact factor: 5.037

4.  Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension.

Authors:  Gaurav Choudhary; Frederick Troncales; Douglas Martin; Elizabeth O Harrington; James R Klinger
Journal:  J Heart Lung Transplant       Date:  2011-05-08       Impact factor: 10.247

5.  The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frederic Lirussi; Françoise Goirand; Luc Rochette; Monique Dumas; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-11       Impact factor: 3.000

6.  Differential cellular responses to protein adducts of naphthoquinone and monocrotaline pyrrole.

Authors:  Lynn S Nakayama Wong; Michael W Lamé; A Daniel Jones; Dennis W Wilson
Journal:  Chem Res Toxicol       Date:  2010-09-20       Impact factor: 3.739

7.  Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Marc Revermann; Eduardo Barbosa-Sicard; Eva Dony; Ralph T Schermuly; Christophe Morisseau; Gerd Geisslinger; Ingrid Fleming; Bruce D Hammock; Ralf P Brandes
Journal:  J Hypertens       Date:  2009-02       Impact factor: 4.844

8.  Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.

Authors:  Zo Rakotoniaina; Pascal Guerard; Frédéric Lirussi; Luc Rochette; Monique Dumas; Françoise Goirand; Marc Bardou
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-10       Impact factor: 3.000

Review 9.  Reactive oxygen species in pulmonary vascular remodeling.

Authors:  Saurabh Aggarwal; Christine M Gross; Shruti Sharma; Jeffrey R Fineman; Stephen M Black
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

10.  Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension?

Authors:  S J Arends; J G M C Damoiseaux; A M Duijvestijn; L Debrus-Palmans; M Vroomen; K A Boomars; H-P Brunner-La Rocca; C P M Reutelingsperger; J W Cohen Tervaert; P van Paassen
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.